Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Dec 8, 2025 that it has been granted usage rights to a block of government-owned mulberry gardens near its Southeast Asia spider silk production facilities. The company will pay a nominal rent and will incorporate the gardens into its production pipeline to supply mulberry leaf feedstock for scaled-up recombinant spider silk manufacturing, including BAM-1 Alpha hybrid yarns.
This land access is intended to improve supply reliability, logistics, and the company's ability to support a recently announced pilot order from a leading performance sports apparel brand as Kraig Labs advances toward broader commercialization.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a hiring initiative on November 25, 2025 to expand production staffing at its Southeast Asia operations as throughput and its production footprint increase. The company is recruiting and training new production staff to support a new production center currently in development, with specialized sericulture training led by Dr. Nirmal Kumar.
The expansion aims to increase capacity, resilience, and commercial production of the company's recombinant spider silk over the coming quarters, and Kraig Labs said it expects to continue adding staff and resources as facilities are developed.
Kraig Biocraft Laboratories (OTCQB: KBLB) is fulfilling an order of its next-generation recombinant spider silk yarns for a confidential pilot program with a globally recognized performance sports apparel brand.
The company is converting part of its spider silk inventory into yarns tailored to the customer's specifications; delivery is expected before the end of the first quarter of 2026. The pilot uses a small, purpose-built quantity intended to demonstrate commercial and performance potential while details remain confidential.
Kraig Biocraft Laboratories (OTCQB: KBLB) confirmed on Nov 3, 2025 that its spider silk production operations in Vietnam remained fully secure and uninterrupted after recent Southeast Asia typhoons.
The company cited its 2024 relocation to protected highlands, complete September relocation from its former Quang Nam facility, and a strategy of multiple parallel production sites as the reasons operations and mulberry feedstock suffered no damage or disruption.
Kraig Biocraft Laboratories (OTCQB: KBLB) promoted Dr. Xiaoli Zhang to Chief Scientist on October 27, 2025 after leading a series of scientific breakthroughs in spider silk-based super materials. Dr. Zhang joined Kraig Labs in October 2024 and, according to the company, accelerated the research program to exceed milestones and advance next-generation fiber and bioengineered materials.
The announcement highlights breakthroughs in spider silk production at the company's operations centers in Southeast Asia and frames the promotion as part of Kraig Labs' push to commercialize sustainable, higher-margin performance materials.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the start of its sixth 2025 spider silk production cycle on October 20, 2025, introducing the first large-scale deployment of its BAM-1 Alpha recombinant spider silk hybrid.
The company says BAM-1 Alpha builds on 2024 breakthroughs to deliver stronger performance and higher silk yields while fitting existing production schedules and infrastructure. The cycle scales parental lines and continues use of diapause egg management to improve efficiency, logistics, and sustained throughput across cycles.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a selective breeding advancement that materially increases recombinant spider silk production throughput. By mating an improved parental strain with a BAM-1 parent, the Company created the BAM-1 Alpha hybrid, which demonstrated 22% higher cocoon shell weight (the company's measure of silk output) and an increase in hybrid vigor of more than 245% versus the original BAM-1. BAM-1 Alpha will be deployed across Kraig's multi-facility production infrastructure to support commercial manufacturing and lower per-unit production cost, while robustness data beyond shell weight remains unquantified.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced plans to add a third recombinant spider silk rearing center as part of a rapid production expansion. The company said it has opened two centers over the past 18 months and is identifying a site for the third facility, expecting to finalize a location within 60 days from the Oct. 6, 2025 announcement. The new center will be located in a leading silk‑production region to leverage local sericulture expertise, and the multi‑facility strategy is intended to enable continuous production and operational redundancy.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has achieved a significant operational milestone by successfully completing its first simultaneous production cycle across two independent rearing centers. The company implemented a strategic two-week offset between facility start times, enabling continuous production of cocoons and silkworm eggs while eliminating downtime between cycles.
This dual-facility model demonstrates Kraig Labs' ability to manage parallel operations with independent teams while maintaining quality standards. The achievement validates their scalable production model and sets the foundation for planned fourth-quarter production expansion. The synchronized operations enhance supply chain resilience and increase throughput capacity, positioning the company to meet growing market demand for recombinant spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced plans to acquire an additional silkworm rearing center as part of its multi-facility expansion strategy. This expansion follows 18 months of significant production growth under Dr. Nirmal Kumar's expertise, after relocating its operating headquarters to Asia's traditional silk-producing regions.
The company has achieved record production volumes and established a scalable foundation for recombinant spider silk manufacturing. The planned facility expansion aims to create a production network for continuous rearing cycles, enhanced reliability, and increased capacity to meet growing global demand across industries including textiles, apparel, defense, and consumer goods.